Commercial: HR+ HER2 | Vanderbilt Television News Archive

Commercial: HR+ HER2 #1318034

CBS Evening News for Tuesday, Apr 20, 2021
View other clips in this broadcast →

Material supplied by VTNA may be used for educational analysis or research only. Any editing, reproduction, publication, rebroadcast, public showing or public display may be prohibited by copyright laws.

Thousands of women with metastatic breast cancer are living in the moment and taking Ibrance Ibrance with an aromatase inhibitor is for postmenopausal women or for men with HR+ HER2- metastatic breast cancer as the first hormonal based therapy Ibrance plus Letrozole significantly delayed disease progression versus Letrozole Ibrance may cause low white blood cell counts that may lead to serious infections. Ibrance may cause severe inflammation of the lungs. Both of these can lead to death. Tell ...

Duration:: 00:00:57

Note to sponsor members: The Vanderbilt Television News Archive video player requires a modern operating system and browser to work properly. If you are experiencing playback problems, check the minimum requirements and adjust your setup accordingly. After adjustments, if you continue to experience problems, please contact us.

Welcome! Above is the abstract of the item that you're interested in viewing from the Vanderbilt Television News Archive's collection. You have three options if you'd like to view this item:

You may request a loan of this video by registering on our website and placing an order.
You may visit the Television News Archive on the Vanderbilt campus to view on-site from the Archive's collection.
If you are associated with a college or university, you may ask your library if they would like to become a sponsor, which would give students and faculty at your institution the ability to view items from our collection.

If you believe that you are associated with a sponsoring college or university and have received this message in error, please let us know.